[
  {
    "ts": null,
    "headline": "Standard BioTools: Outlook Still Murky",
    "summary": "Standard BioTools (LAB) gains $350M from SomaScan sale, with Casdin Capital upping its stake.",
    "url": "https://finnhub.io/api/news?id=3faed9798e160fb29e181505a53e17582150f67b98958de9c235d4cbcde943a0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766912578,
      "headline": "Standard BioTools: Outlook Still Murky",
      "id": 137922366,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1753633862/image_1753633862.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "Standard BioTools (LAB) gains $350M from SomaScan sale, with Casdin Capital upping its stake.",
      "url": "https://finnhub.io/api/news?id=3faed9798e160fb29e181505a53e17582150f67b98958de9c235d4cbcde943a0"
    }
  }
]